December 12, 2018

Opening the door to personalized medicine

Lausanne/Neuchâtel, 10 December 2018—SUN bioscience launches its Gri3D™ platform. Industrialized with CSEM technological support, Gri3D™ enables the large-scale, standardized, rapid, and reliable production of 3-D in vitro organoid cultures from patient stem cells. This groundbreaking, large scale standardizing of organoids represents a key advancement toward truly personalizing medicine.

Nathalie Brandenberg (SB), Sarah Heub (CSEM), Sylke Hoehnel (SB), and Gilles Weder (CSEM)
Press release (PDF)

Related Press

A hand holding a bioreactor to grow vein grafts developed by CSEM and ClexBio

22 February 2024

CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants

The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....

CSEM ACCELERATE 2025 team

4 November 2025

Four future deep-tech start-ups join CSEM’s ACCELERATE Program to turn Swiss innovation into global impact

CSEM unveils the 2025 ACCELERATE Program cohort — four deep-tech ventures transforming Swiss research into real-world solutions....

Soleva van at Neuchatel for the PVmontion congress

12 June 2024

The first 100% self-powered campervan embarks on its Swiss tour on June 14

Soleva, the 100% solar-powered campervan, is equipped with one of the most advanced lightweight solar panel technologies from CSEM. It will start its tour of Switzerland on Friday, June 14, and will p...